ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented PLacental eXpanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company's PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products. It also develops PLX-PAD cells, which are in Phase-II clinical trial for use in the treatment of peripheral and cardiovascular, orthopedic, and pulmonary diseases, as well as for hematological and women's health diseases; and PLX-RAD cells used for acute radiation syndrome treatment of animals, as well as products in pre-clinical trial for the treatment of pre-eclampsia and rotator-cuff repair. The company is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation; and commercialization agreement with CHA Bio&Diostech for conducting clinical trials and commercialization of PLX-PAD products in South Korea. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.
Pacific Booker Minerals Inc. is engaged in the exploration of mineral property interests in Canada. It primarily holds interest in the Morrison Project, a copper/gold exploration project covering an area of 65 square kilometers located in British Columbia. The company was formerly known as Booker Gold Explorations Limited and changed its name to Pacific Booker Minerals Inc. in February 2000. Pacific Booker Minerals Inc. was incorporated in 1983 and is headquartered in Vancouver, Canada.
American Electric Technologies, Inc. provides power delivery solutions to the energy industry in the United States and internationally. It operates in three segments: Technical Products and Services (TP&S), Electrical and Instrumentation Construction (E&I), and American Access Technologies (AAT). The TP&S segment designs, manufactures, markets, and provides low and medium voltage switchgears, generator control and distribution switchgears, motor control centers, powerhouses, bus ducts, variable frequency AC drives, variable speed DC drives, program logic control based automation systems, human machine interface, and specialty panels to distribute the flow of electricity and protect electrical equipment, such as motors, transformers, and cables. It also offers services, such as electrical equipment retrofits, upgrades, start-ups, testing, and troubleshooting of substations, switchgear, drives, and control systems. The E&I segment provides electrical and instrumentation construction and installation services to land and marine based markets of the oil and gas, and other commercial and industrial markets. Its services include electrical and instrumentation turnarounds, maintenance, renovation, and new construction; and marine based oil and gas services, such as electrical system rig-ups, modifications, and start-ups, as well as testing for vessels, drilling rigs, and production modules. The AAT segment manufactures and markets zone cabling and wireless telecommunication enclosures, and formed metals products; operates a precision sheet metal fabrication and assembly operation; and provides services, such as precision computer numerical controlled stamping, bending, assembling, painting, powder coating, and silk screening to engineering, technology, and electronics companies. The company is headquartered in Houston, Texas.
Freescale Semiconductor, Ltd. provides embedded processing solutions for automotive, networking, industrial, and consumer markets worldwide. The company's embedded processor products comprise microcontrollers, such as ultra low power, low end 8-bit products to higher performance 16-bit, and 32-bit products with on-board flash memory, which provide the digital logic or intelligence for electronic applications and controlling electronic equipment; single-and multi-core microprocessors; and applications processors with embedded memory, and special purpose hardware and software for multimedia applications. It also offers wireless connectivity products for low power wireless communications functionality; communications processors that perform tasks related to control and management of digital data, and network interfaces; and radio frequency devices, such as power transistors, amplifiers, receivers, and tuners. In addition, the company provides analog and mixed-signal products, such as system-basis chips, auto engine control, stability and braking solutions, battery and power management, and motor control devices, CAN/LIN interface solutions, radar solutions, and signal conditioners; and sensors comprising pressure, inertial, magnetic, proximity, and gyroscopic sensors. Further, the company offers digital signal processors to perform baseband modem processing; digital signal controllers, which offer solutions for digital power conversion, motor control, and other applications in consumer, industrial, and healthcare markets. It serves original equipment manufacturers, distributors, original design manufacturers, and contract manufacturers through its direct sales force and distributors. The company was formerly known as Freescale Semiconductor Holdings I, Ltd. and changed its name to Freescale Semiconductor, Ltd. in April 2012. The company was incorporated in 2006 and is based in Austin, Texas.
Semler Scientific, Inc., a medical risk-assessment company, develops, manufactures, and markets various patented products to identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services in the United States. Its products include FloChec that is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians. The company provides its FloChec product and services to its customers through its salespersons and through its co-exclusive distributor. Semler Scientific, Inc. was founded in 2007 and is headquartered in Portland, Oregon.
Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Amira Nature Foods Ltd is engaged in processing, distributing, and marketing packaged specialty rice and other food products. The company provides various types of basmati rice, specialty rice and value add meals, ready-to-eat snacks, ready to heat means, edible oils, organics, and dairy products for retailers under the Amira brand; and non-basmati rice. It also sells bulk commodities, including wheat, barley, legume, maize, sugar, soybean meal, onion, potatos, and millets to trading firms. Amira Nature Foods Ltd sells its products to distributors and retail chains in India; and buyers in the Asia Pacific, the Middle East, Europe, North Africa, and North America. The company was founded in 1915 and is based in Dubai, the United Arab Emirates.
Transgenomic, Inc. operates as a biotechnology company that focuses advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular technologies and clinical and research services in the United States, Italy, the United Kingdom, Germany, France, and internationally. It operates in two segments, Laboratory Services and Genetic Assays and Platforms. The Laboratory Services segment specializes in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. This segment also provides pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted by pharmaceutical companies. It employs various genomic testing service technologies, including ICE COLD-PCR technology, a proprietary platform technology that enables detection of multiple unknown mutations from virtually any sample type, including tissue biopsies, blood, cell-free DNA, and circulating tumor cells. The Genetic Assays and Platforms segment offers the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. The company sells its products through direct sales, support staff, dealers, and distributors to academic and medical institutions; and pharmaceutical, biotech, and commercial companies. Transgenomic, Inc. has a strategic collaboration agreement with PDI, Inc. The company was founded in 1997 and is headquartered in Omaha, Nebraska.
Electronic Arts Inc. develops, markets, publishes, and distributes game software content and services for video game consoles, personal computers, mobile phones, and tablets. The company operates through EA Games, EA SPORTS, Maxis, PopCap, and All Play segments. It provides action-adventure, casual, family, fantasy, first-person shooter, horror, science fiction, role-playing, racing, simulation, sports, and strategy games under the Battlefield, Mass Effect, Need for Speed, Dragon Age, The Sims, Bejeweled, and Plants v. Zombies, as well as EA SPORTS, Battlefield 4, FIFA Street, Maxis, Madden NFL, Medal of Honor, and Star Wars brand names. The company also offers casual games, such as cards, puzzles, and word games through its pogo.com, as well as on other platforms; and digital content and Internet-based advertising services. The company was founded in 1982 and is headquartered in Redwood City, California.